Pertussis Treatment with Azithromycin Allergy
For patients with azithromycin (Z-Pak) allergy, use trimethoprim-sulfamethoxazole (TMP-SMZ) for 14 days as the alternative treatment for pertussis, provided the patient is older than 2 months of age.
Primary Alternative: TMP-SMZ
According to CDC guidelines, TMP-SMZ is the recommended alternative antibiotic for patients who cannot tolerate macrolides or have contraindications to them 1. The evidence demonstrates that TMP-SMZ is effective in eradicating Bordetella pertussis from the nasopharynx 2, 3.
Dosing Regimen:
- Infants >2 months and children: TMP 8 mg/kg per day, SMZ 40 mg/kg per day in 2 divided doses for 14 days
- Adults: TMP 320 mg, SMZ 1600 mg per day in 2 divided doses for 14 days
Critical Age Restriction:
TMP-SMZ is contraindicated in infants <2 months due to kernicterus risk 1. This is a non-negotiable safety concern.
If Patient is <2 Months Old with Macrolide Allergy
This presents a challenging clinical scenario. The CDC guidelines indicate that:
First, clarify the type of "allergy": If the reaction to azithromycin was gastrointestinal intolerance (nausea, vomiting, diarrhea) rather than true IgE-mediated hypersensitivity, consider:
If true IgE-mediated allergy to all macrolides: Recent case reports demonstrate that azithromycin desensitization is feasible in carefully selected infants when alternative agents are unsuitable 4. This requires:
- Multidisciplinary consultation (allergy/immunology, infectious disease)
- Inpatient monitoring with resuscitation equipment available
- Modified protocols with extended infusion/observation intervals if initial attempts fail
Important Clinical Caveats
Cross-Reactivity Among Macrolides
Erythromycin is contraindicated if there is history of hypersensitivity to ANY macrolide agent 1. However, the guidelines note this applies to true hypersensitivity reactions. If the azithromycin "allergy" was:
- GI intolerance: Try erythromycin or clarithromycin
- True allergic reaction (rash, angioedema, anaphylaxis): Avoid all macrolides
Erythromycin-Specific Risks in Neonates
If considering erythromycin in infants <1 month, counsel parents about infantile hypertrophic pyloric stenosis (IHPS) risk 1. In one cohort study, 7 out of 157 erythromycin-exposed infants developed IHPS versus 0 out of 125 unexposed infants 1. Monitor for feeding intolerance, projectile vomiting, and visible peristaltic waves.
Emerging Macrolide Resistance
Recent evidence shows macrolide resistance in certain regions 5, 6. If a patient fails to improve on macrolide therapy despite documented compliance, consider TMP-SMZ as second-line even if macrolide allergy is not present 5, 6.
Treatment Algorithm
- Age >2 months with azithromycin allergy → TMP-SMZ for 14 days
- Age <2 months with GI intolerance to azithromycin → Erythromycin for 14 days (monitor for IHPS)
- Age <2 months with true IgE-mediated macrolide allergy → Consider azithromycin desensitization in consultation with allergy/immunology
- Age 1-2 months with macrolide allergy → Clarithromycin for 7 days (if >1 month) OR TMP-SMZ for 14 days (if >2 months)
Key Points on Antibiotic Efficacy
Antibiotics eradicate B. pertussis and prevent transmission but do not alter the clinical course once symptoms begin 2, 3. The primary goals are:
- Rendering the patient non-infectious
- Preventing spread to vulnerable contacts (especially infants)
- Reducing duration of bacterial shedding
Treatment should be initiated as early as possible, ideally within the first 3 weeks of illness when bacterial loads are highest.